SD Biosensor and SJL Partners Acquire Meridian Bioscience for $1.53B
July 7, 2022
A consortium led by SD Biosensor and private equity firm SJL Partners agreed to acquire Meridian Bioscience in an all-cash transaction valued at approximately $1.53 billion ( $34.00 per share). The deal will take Meridian private and is intended to accelerate SD Biosensor's entry into the U.S. in-vitro diagnostics market while leveraging Meridian's U.S. distribution network and product portfolio.
- Buyers
- SD Biosensor, Inc., SJL Partners LLC
- Targets
- Meridian Bioscience, Inc.
- Sellers
- Meridian Bioscience shareholders
- Industry
- Medical Devices
- Location
- Ohio, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Eli Lilly to Acquire Merida Biosciences
August 31, 2026
Biotechnology
Eli Lilly and Company has agreed to acquire Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and contingent milestone payments. The acquisition is intended to expand Lilly’s precision immunology platform for selectively targeting disease-causing antibodies across autoimmune and allergic conditions, including Graves’ disease and thyroid eye disease.
-
Sherlock Biosciences Acquires Sense Biodetection
February 1, 2023
Biotechnology
Sherlock Biosciences has acquired Sense Biodetection to accelerate commercialization of CRISPR-enabled, instrument-free molecular diagnostics by integrating Sense’s Veros rapid, instrument-free test platform, chemistry and manufacturing capabilities into Sherlock’s platform. Terms were not disclosed; Sense is headquartered in Oxford, United Kingdom with additional facilities in Cambridge (UK) and Milford, Massachusetts.
-
Merck Acquires Imago BioSciences for $1.35 Billion
November 21, 2022
Biotechnology
Merck (MSD) entered into a definitive agreement to acquire clinical-stage biopharmaceutical company Imago BioSciences in an all-cash deal valued at approximately $1.35 billion (=$36.00 per share). Merck will commence a tender offer for all outstanding shares, with the transaction expected to close in the first quarter of 2023, subject to customary conditions.
-
Pace Life Sciences Acquires Meridian BioGroup
August 18, 2022
Healthcare Services
Pace Life Sciences, a CDMO and subsidiary of Pace Science and Technology Company, has acquired Meridian BioGroup, a validation, regulatory, and compliance consulting provider based in Frederick, Maryland. The deal expands Pace's regulatory, quality and validation capabilities to better support biotechnology and pharmaceutical clients across development and commercialization.
-
Bioscript Group (backed by Sovereign Capital Partners) Acquires Meridian HealthComms
April 19, 2022
Healthcare Services
Bioscript Group, a Sovereign Capital Partners-backed healthcare communications platform headquartered in Macclesfield, has acquired Meridian HealthComms. The deal is Bioscript's third acquisition since Sovereign backed the management team in March 2021 and expands the group's geographic footprint and service capabilities in medical communications, regulatory writing and market access.
-
Merck & Co., Inc. Acquires VelosBio Inc.
November 5, 2020
Biotechnology
Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.